SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0000950170-24-138446
Filing Date
2024-12-19
Accepted
2024-12-19 16:09:30
Documents
13
Period of Report
2024-12-19
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.02: Results of Operations and Financial Condition
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K engn-20241219.htm   iXBRL 8-K 54716
2 EX-99.1 engn-ex99_1.htm EX-99.1 79864
3 GRAPHIC img7790613_0.jpg GRAPHIC 13126
  Complete submission text file 0000950170-24-138446.txt   324028

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT engn-20241219.xsd EX-101.SCH 55707
15 EXTRACTED XBRL INSTANCE DOCUMENT engn-20241219_htm.xml XML 6503
Mailing Address 4868 RUE LEVY, SUITE 220 SAINT-LAURENT A8 H4R 2P1
Business Address 4868 RUE LEVY, SUITE 220 SAINT-LAURENT A8 H4R 2P1 (514) 332-4888
enGene Holdings Inc. (Filer) CIK: 0001980845 (see all company filings)

IRS No.: 000000000 | State of Incorp.: Z4 | Fiscal Year End: 1031
Type: 8-K | Act: 34 | File No.: 001-41854 | Film No.: 241563365
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)